Asset Details
Do you wish to reserve the book?
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options
Do you wish to request the book?
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
High-Grade Endometrial Cancer: Molecular Subtypes, Current Challenges, and Treatment Options
2024
Overview
Although many recent advancements have been made in women’s health, perhaps one of the most neglected areas of research is the diagnosis and treatment of high-grade endometrial cancer (EnCa). The molecular classification of EnCa in concert with histology was a major step forward. The integration of profiling for mismatch repair deficiency and Human Epidermal Growth Factor 2 (HER2) overexpression, can further inform treatment options, especially for drug resistant recurrent disease. Recent early phase trials suggest that regardless of subtype, combination therapy with agents that have distinct mechanisms of action is a fruitful approach to the treatment of high-grade EnCa. Unfortunately, although the importance of diagnosis and treatment of high-grade EnCa is well recognized, it is understudied compared to other gynecologic and breast cancers. There remains a tremendous need to couple molecular profiling and biomarker development with promising treatment options to inform new treatment strategies with higher efficacy and safety for all who suffer from high-grade recurrent EnCa.
Publisher
Springer International Publishing
Subject
/ Biomarkers, Tumor - metabolism
/ Endometrial Neoplasms - classification
/ Endometrial Neoplasms - drug therapy
/ Endometrial Neoplasms - genetics
/ Endometrial Neoplasms - metabolism
/ Endometrial Neoplasms - pathology
/ Endometrial Neoplasms - therapy
/ Female
/ Gynecologic Oncology: Review (Invited)
/ Humans
/ Medicine
